Catapult Growth Fund, a newly launched £30m ECF run by Catapult Venture Managers has led an investment in Oxford Genome Sciences Ltd (OGeS). Existing investors South East Growth Fund and Oxford Capital Partners also participated in the funding round which follows a series-B round in May 2005.
Deal includes three manufacturing facilities located in Spain, which employ around 140 staff
GP acquired the care home group from Swiss Prime Site and will be the company's sole shareholder
Iris, Idinvest and historical backers invest in the manager of the eponymous social media app
GP uses its Mérieux Participations 3 fund, which held a first close on €200m in 2018